Target intelligence / Profile preview

Skeletal muscle nicotinic acetylcholine receptor (nAChR (muscle-type), or muscle-type nAChR)

Target
nAChR (muscle-type), or muscle-type nAChR
Molecular classification
Ion channel, Receptor, Ligand-gated ion channel, Cys-loop receptor family
01

Overview

The skeletal muscle nicotinic acetylcholine receptor is a ligand-gated ion channel found at the neuromuscular junction and is the key mediator of fast synaptic transmission between motor neurons and skeletal muscle fibers. It is a heteropentameric protein complex typically composed of two α1, one β1, one δ, and one ε (adult) or γ (fetal) subunits. Upon binding two molecules of acetylcholine released from motor neurons, the receptor undergoes a conformational change that opens its ion channel pore, allowing rapid influx of sodium ions and efflux of potassium ions, initiating muscle membrane depolarization and triggering muscle contraction. It is essential for voluntary movement, and its malfunction or blockade is linked to pathologies such as myasthenia gravis, congenital myasthenic syndromes, and paralysis by neurotoxins or clinical muscle relaxants[1][3][5][8][9].

Other names
muscle-type nicotinic acetylcholine receptormuscle nAChRneuromuscular nicotinic receptornicotinic acetylcholine receptor (muscle type)muscle AChR
02

Mechanism of action

Agonists open the ion channel to allow cation influx (mainly Na^+, some K^+, and Ca^2+^), leading to depolarization and muscle contraction; Antagonists compete for the acetylcholine binding site (competitive block) or bind irreversibly (non-competitive, e.g., alpha-bungarotoxin), leading to muscle relaxation or paralysis[1][5][6][9].

03

Biological functions

Signal transductionNeuromuscular transmissionMuscle contractionSynaptic transmission
04

Disease associations

Neurodegenerative diseaseNeuromuscular disease (e.g., myasthenia gravis, congenital myasthenic syndromes)Other (muscle atrophy, denervation)
05

Safety considerations

Prolonged blockade leads to paralysis and apneadepolarizing agents (e.g., succinylcholine) risk hyperkalemia, malignant hyperthermia, and prolonged paralysis in susceptible patientsrisk of allergic/anaphylactic reaction to neuromuscular blockersvariable sensitivity in congenital disease and liver/renal impairment[8].
06

Interacting drugs

Acetylcholine (agonist)

8 more in the full profile.

07

Biomarkers

Presence of anti-nAChR antibodies in serum for myasthenia gravis diagnosisnAChR subunit expression in muscle biopsies for congenital myasthenic syndromes[8].

Beyond the preview

Go deeper on Skeletal muscle nicotinic acetylcholine receptor (nAChR (muscle-type), or muscle-type nAChR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Skeletal muscle nicotinic acetylcholine receptor (nAChR (muscle-type), or muscle-type nAChR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call